Advertisement
Research Article

Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial

  • James A. McIntyre,

    Affiliation: Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa

    X
  • Mark Hopley,

    Affiliation: Boehringer Ingelheim, Johannesburg, South Africa

    X
  • Daya Moodley,

    Affiliation: Department of Obstetrics and Gynaecology, Nelson Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa

    X
  • Marie Eklund,

    Affiliation: Boehringer Ingelheim, Johannesburg, South Africa

    X
  • Glenda E. Gray,

    Affiliation: Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa

    X
  • David B. Hall,

    Affiliation: Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, United States of America

    X
  • Patrick Robinson,

    Affiliation: Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, United States of America

    X
  • Douglas Mayers,

    Affiliation: Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, United States of America

    Current address: Idenix Pharmaceuticals, Cambridge, Massachusetts, United States of America

    X
  • Neil A. Martinson mail

    martinson@hivsa.com

    Affiliations: Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

    X
  • Published: October 27, 2009
  • DOI: 10.1371/journal.pmed.1000172
  • Featured in PLOS Collections

About the Authors

James A. McIntyre, Glenda E. Gray, Neil A. Martinson
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
Mark Hopley, Marie Eklund
Boehringer Ingelheim, Johannesburg, South Africa
Daya Moodley
Department of Obstetrics and Gynaecology, Nelson Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
David B. Hall, Patrick Robinson, Douglas Mayers
Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, United States of America
Neil A. Martinson
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Corresponding Author

Email: martinson@hivsa.com

Competing Interests

M. Hopley, M. Ekelund, D. B. Hall, and P. Robinson are employed by Boehringer Ingelheim, the sponsor of the study, and D. Mayers was employed by Boehringer Ingelheim at the time of the study. Employees of the sponsor were involved in protocol design, were responsible for data management and statistical analyses, and assisted with the preparation of the paper. J. A. McIntyre and G. E. Gray have received research funding, travel grants and speaker's honoraria from Boehringer Ingelheim and Glaxo SmithKline. N. A. Martinson and D. Moodley declare no competing interests.

Author Contributions

ICMJE criteria for authorship read and met: JMc MH DMo ME GEG DH PR DMa NAM. Agreed with manuscript s results and conclusions: JMc MH DMo ME GEG DH PR DMa NAM. Designed the experiments/the study: NAM DMo ME JMc PR DH DMa. Analyzed the data: NAM JMc MH DH DMa GEG. Collected data/did experiments for the study: JMc ME DH DMa GEG. Enrolled Patients: DMo ME GEG. Wrote the first draft of the paper: NAM MH JMc. Contributed to the writing of the paper: NAM JMc MH DMo PR ME DH DMa GEG. MH was responsible for the conduct of the trial and, with ME and DMa, oversaw data management. Analysis was undertaken by DH and DMa, directed by JMc, NAM, and MH with assistance from GEG. NAM and DMo assisted in recruitment of participants. NAM, MH, and JMc, wrote the paper with assistance from DH, DMa, ME, DMo, PR, and GEG. The sponsor has given an assurance that all authors have full access to the trial dataset.